Biomarin Pharmaceutical Inc. (BMRN)
  • Россия
  • Украина

Biomarin Pharmaceutical Inc. (BMRN)

Contact Details

770 Lindaro St, San Rafael, California, USA 94901-3991
(415) 506-6700
770 Lindaro St, San Rafael, California, USA 94901-3991

General Information

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin`s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.

Contact Information

Phone(415) 506-6700
Customer Service Phone(800) 947-5227
Website 1
Thomson Reuters PermID4295912660


NamePositionTotal Annual CompensationYearPercent Change in Compensation
CFO and Executive VP$3,183,7312014-21.0%
Divisional Executive VP$2,879,9452014-21.0%
Chief Medical Officer and Executive VP$3,575,0942014-25.9%
Other Executive Officer and Senior VP$2,677,30120140.3%

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsJuly 25, 2012$0
Department of Veterans AffairsDrugs and BiologicalsAugust 25, 2006$0

Corporate Data


  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations
  • Enzyme And Isoenzyme Diagnostic Agents

Company Size

Sales Volume$885 million


Ticker SymbolBMRN
ExchangeNASDAQ Global Select Market
Type of EntityFor Profit Organization
Type of OwnershipNot Tax Exempt Corporate Entity
Federal AwardsReceives Contracts
Other CategorizationsManufacturer of Goods
State of IncorporationDelaware
Year Founded1997


Previous Close85.21
Bid83.17 x 800
Ask83.20 x 10,500
Day`s Range82.67 - 86.28
52-Week Range64.74 - 149.13
Average Volume (1M)1,634,617
Market Cap.$13,769.2 Million
Last Dividend Amount0
1y Target Price Est.155.29


Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue227,204208,904250,523203,264
Cost of Revenue42,59836,71939,87832,813
Gross Profit184,606172,185210,645170,451
Research Development176,118158,713157,901142,074
Selling General and Administrative113,90794,044101,51492,806
Depreciation and Amortization(20,422)1,301-1,431
Other Operating Expenses(186,268)-15,470-
Total Operating Expenses125,933290,777314,763269,124
Other Income/Expenses Net----
Earnings Before Interest and Taxes101,271(81,873)(64,240)(65,860)
Interest Expense9,3339,44710,0029,462
Income Before Tax92,966(90,443)(82,544)(74,703)
Income Tax Expense24,349483(555)(7,202)
Minority Interest----
Net Income from Continuing Ops68,617(90,926)(81,989)(67,501)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income68,617(90,926)(81,989)(67,501)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares68,617(90,926)(81,989)(67,501)